Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Recurrence 1Penile Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Anus Neoplasms 1Anal Canal Carcinoma 1

Interventions

Oxaliplatin 10Gemcitabine 8Cisplatin 7Hepatectomy 6Fluorouracil 6Radiofrequency Ablation 5Liver Transplantation 5Irinotecan 5Capecitabine 5lenvatinib 4Paclitaxel 4Neoadjuvant Therapy 4Folfox protocol 4Cetuximab 4Aspirin 4tislelizumab 3Surgical Procedures, Operative 3Nivolumab 3Carboplatin 3titanium silicide 2durvalumab 2apatinib 2Trastuzumab 2S 1 (combination) 2Leucovorin 2Lamivudine 2Introns 2Ethiodized Oil 2Drug Therapy 2DNA, Mitochondrial 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × MEDI0457 × Gastrointestinal × Clear all
NCT03439085 2024-07-09

DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers

M.D. Anderson Cancer Center

Phase 2 Terminated
41 enrolled 13 charts
GastrointestinalGenitourinaryGynecologic

Anal Canal Carcinoma, Anus Neoplasms, Uterine Cervical Neoplasms, Neoplasm Metastasis, Neoplasms, Penile Neoplasms, Recurrence, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡